Table 5.
Target organ/tissue | Male-specific carcinogens inducing tumors in femalesb | Female-specific carcinogens inducing tumors in males | ||
---|---|---|---|---|
Liver | 7/16 | 44% | 7/8 | 88% |
Thyroid | 2/9 | 22% | 2/5 | 40% |
Kidney | 14/42 | 33% | 1/5 | 20% |
Intestine | 3/5 | 60% | 1/1 | 100% |
Forestomach | 1/3 | 33% | 0/0 | – |
Leukemia,Lymphoma | 4/10 | 40% | 9/15 | 60% |
Adrenal gland | 4/12 | 33% | 5/8 | 63% |
Lung | 5/6 | 83% | 6/8 | 75% |
Vascular system | 4/5 | 80% | 1/2 | 50% |
Urinary bladder | 2/4 | 50% | 4/6 | 67% |
Mesothelium | 11/15 | 73% | 0/0 | – |
Brain | 1/3 | 33% | 2/2 | 100% |
Nasal cavity | 0/4 | 0% | 0/0 | – |
Spleen | 1/4 | 25% | 1/1 | 100% |
Pancreas | 3/11 | 27% | 0/0 | – |
Pituitary | 0/1 | 0% | 3/4 | 75% |
Skin | 11/14 | 79% | 1/2 | 50% |
Subcutaneous tissue | 3/4 | 75% | 1/1 | 100% |
Oral cavity | 1/2 | 50% | 2/2 | 100% |
Ureter | 1/1 | 100% | 0/0 | – |
Weighted average | 46% | 66% |
Gender-specific target site responses (http://ntp.niehs.nih.gov/) were analyzed for additional targets in the same gender and the same bioassay.
first column the fraction of gender-specific carcinogens (see Table 1) inducing tumors at additional sites in the other gender per total number of gender-specific targets. The second column gives the % carcinogens inducing tumors at additional sites.